dovitinib联合氟维司汀治疗绝经后HR+、HER2−乳腺癌患者,这些患者在既往内分泌治疗期间或之后发生进展,该研究是一项随机、安慰剂对照研究

IF 6.1 1区 医学 Q1 ONCOLOGY
A. Musolino, M. Campone, P. Neven, N. Denduluri, C. Barrios, J. Cortés, K. Blackwell, H. Soliman, Z. Kahán, H. Bonnefoi, M. Squires, Yong Zhang, S. Deudon, M. Shi, F. André
{"title":"dovitinib联合氟维司汀治疗绝经后HR+、HER2−乳腺癌患者,这些患者在既往内分泌治疗期间或之后发生进展,该研究是一项随机、安慰剂对照研究","authors":"A. Musolino, M. Campone, P. Neven, N. Denduluri, C. Barrios, J. Cortés, K. Blackwell, H. Soliman, Z. Kahán, H. Bonnefoi, M. Squires, Yong Zhang, S. Deudon, M. Shi, F. André","doi":"10.1186/s13058-017-0807-8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9222,"journal":{"name":"Breast Cancer Research","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2017-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"84","resultStr":"{\"title\":\"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy\",\"authors\":\"A. Musolino, M. Campone, P. Neven, N. Denduluri, C. Barrios, J. Cortés, K. Blackwell, H. Soliman, Z. Kahán, H. Bonnefoi, M. Squires, Yong Zhang, S. Deudon, M. Shi, F. André\",\"doi\":\"10.1186/s13058-017-0807-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9222,\"journal\":{\"name\":\"Breast Cancer Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2017-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"84\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-017-0807-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-017-0807-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 84

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breast Cancer Research
Breast Cancer Research 医学-肿瘤学
自引率
0.00%
发文量
76
期刊介绍: Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信